| Dr Stephan B Rosenfeld, MD | |
|
3232 N Northhills Blvd, Fayetteville, AR 72703-4005 | |
| (479) 587-1700 | |
| (479) 587-1366 |
| Full Name | Dr Stephan B Rosenfeld |
|---|---|
| Gender | Male |
| Speciality | Medical Oncology |
| Experience | 28 Years |
| Location | 3232 N Northhills Blvd, Fayetteville, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083685283 | NPI | - | NPPES |
| 205831407 | Medicaid | MO | |
| 146332001 | Medicaid | AR | |
| 100177440A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | E3326 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Hospital Northwest Arkansas | Rogers, AR | Hospital |
| Washington Regional Medical Center | Fayetteville, AR | Hospital |
| Northwest Medical Center-springdale | Springdale, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Highlands Oncology Group Pa | 7416976196 | 63 |
News Archive
New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment.
Targeted alpha therapy has the potential to selectively eliminate HIV infected cells from the central nervous system, according to a recent study co-authored by the JRC. The study shows that a specific human antibody labelled with the alpha emitter bismuth-213 can penetrate the blood brain barrier and selectively target and destroy HIV-infected cells while sparing non-infected healthy cells.
Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also receiving another anticoagulant resulted in reduction in the size of damage to the heart muscle at 30 days, while a procedure that involved use of a catheter to remove the blood clot blocking that coronary artery did not produce these results, according to a study appearing in JAMA.
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
› Verified 9 days ago
| Entity Name | Highlands Oncology Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346211323 PECOS PAC ID: 7416976196 Enrollment ID: O20051111000204 |
News Archive
New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment.
Targeted alpha therapy has the potential to selectively eliminate HIV infected cells from the central nervous system, according to a recent study co-authored by the JRC. The study shows that a specific human antibody labelled with the alpha emitter bismuth-213 can penetrate the blood brain barrier and selectively target and destroy HIV-infected cells while sparing non-infected healthy cells.
Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also receiving another anticoagulant resulted in reduction in the size of damage to the heart muscle at 30 days, while a procedure that involved use of a catheter to remove the blood clot blocking that coronary artery did not produce these results, according to a study appearing in JAMA.
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephan B Rosenfeld, MD 3232 N Northhills Blvd, Fayetteville, AR 72703-4005 Ph: (479) 587-1700 | Dr Stephan B Rosenfeld, MD 3232 N Northhills Blvd, Fayetteville, AR 72703-4005 Ph: (479) 587-1700 |
News Archive
New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment.
Targeted alpha therapy has the potential to selectively eliminate HIV infected cells from the central nervous system, according to a recent study co-authored by the JRC. The study shows that a specific human antibody labelled with the alpha emitter bismuth-213 can penetrate the blood brain barrier and selectively target and destroy HIV-infected cells while sparing non-infected healthy cells.
Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also receiving another anticoagulant resulted in reduction in the size of damage to the heart muscle at 30 days, while a procedure that involved use of a catheter to remove the blood clot blocking that coronary artery did not produce these results, according to a study appearing in JAMA.
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
› Verified 9 days ago
Lauren Cantwell Paulk, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1706 E Joyce Blvd Ste 2, Fayetteville, AR 72703 Phone: 479-966-9370 | |
David R Crittenden, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1408 E Elmwood Dr, Fayetteville, AR 72703 Phone: 479-442-0759 | |
Kim R Agee, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 3344 N Futrall Dr, Fayetteville, AR 72703 Phone: 479-521-8200 Fax: 479-582-7310 | |
Dr. David A Churchill, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3211 N Northhills Blvd, Suite 110, Fayetteville, AR 72703 Phone: 479-571-4338 Fax: 479-571-4015 | |
Dr. Marlan Levan Rhame Iii, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1100 N College Ave, Fayetteville, AR 72703 Phone: 479-443-4301 Fax: 479-587-5929 | |
Waqar M Mehal, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 12 E Appleby, Suite 101, Fayetteville, AR 72703 Phone: 479-463-4444 Fax: 479-463-4499 | |
Dr. Juan I Lombeida, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3232 N North Hills Blvd, Fayetteville, AR 72703 Phone: 479-587-1700 |